Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to shrink recurrent ovarian tumors

NCT ID NCT07714668

Not yet recruiting Disease control Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific type of ovarian cancer and have had limited prior therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental antibody-drug conjugate called SYS6041, given alone or with chemotherapy (carboplatin, paclitaxel) and/or bevacizumab and/or enlonstobart
What this could lead to
If successful, this could point toward a new treatment option for women with recurrent ovarian cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not confirm benefit. Side effects from the combination therapies could be significant, and the experimental drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER RECURRENT OVARIAN CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.